Spyre Therapeutics, Inc.
SYRE
$44.07
$4.1810.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 5.44% | 21.58% | 40.58% | 81.71% | 125.73% |
| Gross Profit | -5.44% | -21.58% | -40.58% | -83.06% | -128.53% |
| SG&A Expenses | 4.66% | -5.97% | -3.96% | 6.66% | 32.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.27% | 14.65% | 28.47% | 45.56% | 76.01% |
| Operating Income | -5.27% | -14.65% | -28.47% | -46.24% | -77.33% |
| Income Before Tax | 25.36% | 30.66% | -11.22% | 42.63% | 38.62% |
| Income Tax Expenses | -129.41% | -128.00% | -88.57% | -90.48% | 296.15% |
| Earnings from Continuing Operations | 25.39% | 30.68% | -11.20% | 42.64% | 38.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.39% | 30.68% | -11.20% | 42.64% | 38.60% |
| EBIT | -5.27% | -14.65% | -28.47% | -46.24% | -77.33% |
| EBITDA | -- | 68.60% | 32.61% | -9.72% | -77.83% |
| EPS Basic | 38.50% | -121.98% | -409.72% | 94.55% | 94.72% |
| Normalized Basic EPS | 42.78% | 64.09% | 79.55% | 89.53% | 89.36% |
| EPS Diluted | 38.50% | -121.98% | -409.72% | 94.55% | 94.72% |
| Normalized Diluted EPS | 42.78% | 64.09% | 79.55% | 89.53% | 89.36% |
| Average Basic Shares Outstanding | 36.19% | 59.21% | 122.73% | 251.62% | 583.95% |
| Average Diluted Shares Outstanding | 36.19% | 59.21% | 122.73% | 251.62% | 583.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |